Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
M D Anderson Cancer Center, Houston, Texas, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Smilow Cancer Hospital Care center at Derby, Derby, Connecticut, United States
Smilow Cancer Hospital Care center at Fairfield, Fairfield, Connecticut, United States
Austin Health, Melbourne, Victoria, Australia
Medizinische Universitaet Wien, Vienna, Austria
Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria
Hunan Cancer Hospital, Changsha, Hunan, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Fudan University Shanghai Cancer Center ( Site 2500), Shanghai, Shanghai, China
Women s Hospital School of Medicine Zhejiang University ( Site 2511), Hangzhou, Zhejiang, China
Anhui Cancer Hospital-Gynecological Oncology ( Site 2509), Hefei, Anhui, China
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States
Tufts Medical Center, Boston, Massachusetts, United States
Shanghai East Hospital, Shanghai, Shanghai, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.